Document is current
Any future updates will be listed below
-
Authors
Collins, Evan https://orcid.org/0000-0003-0774-6975
Ji, Jungyong https://orcid.org/0009-0005-8917-502X
Kim, Sung-Gwang https://orcid.org/0009-0000-5252-9270
Witten, Jacob https://orcid.org/0000-0003-0037-5999
Kim, Seonghoon
Zhu, Richard https://orcid.org/0009-0003-9455-1814
Park, Peter https://orcid.org/0000-0001-5671-9354
Jung, Minjun https://orcid.org/0009-0007-5989-0721
Park, Aron
Manan, Rajith S. https://orcid.org/0000-0001-7081-0138
Rudra, Arnab https://orcid.org/0000-0002-1704-5534
Keum, Gyochang
Bang, Eun-Kyoung https://orcid.org/0000-0002-0339-0740
Jin, Jun-O https://orcid.org/0000-0003-4216-8111
Jeang, William J. https://orcid.org/0000-0002-5401-8535
Langer, Robert https://orcid.org/0000-0003-4255-0492
Anderson, Daniel G. https://orcid.org/0000-0001-5629-4798
Im, Wonpil https://orcid.org/0000-0001-5642-6041
-
Funding
Funding for this research was provided by:
Sanofi
U.S. Department of Health & Human Services | National Institutes of Health (R33AI161805-05)
MIT Jameel Clinic
- License Information
-
More Information
Article History
Received: 7 June 2025
Accepted: 16 January 2026
First Online: 28 January 2026
Competing interests
: D.G.A. receives research funding from Sanofi and is a founder of Orna Therapeutics, Soufflé Therapeutics, and Combined Therapeutics. R.L. is a co-founder and former member of the board of directors of Moderna. R.L. also serves on the board and has equity in Particles for Humanity. For a full list of entities with which R.L. is involved, compensated or uncompensated, see . W.I. is a co-founder and CEO of MolCube Inc. The remaining authors have no competing interests to declare.
